NGL Fine-Chem Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from NGL Fine-Chem Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹87Over the last 3 years, every ₹100 of reported profit came with ₹87 of operating cash.
Lower than 65% of Healthcare companies in India.
Self-Funding Ratio
0.5×Over the last 3 years its own operating cash paid for 50% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 81% of Healthcare companies in India.
Cash Locked Ratio
₹25For every ₹100 of sales, ₹25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹24 tied up three years earlier.
More money tied up than 54% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹13Sales grew 81% in 3 years; of every extra ₹100 of sales, ₹13 became extra profit.
Lower than 62% of Healthcare companies in India.
Asset Productivity Ratio
+81% / +90%In 3 years sales changed by +81% while total assets changed by +90%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.7×Debt due within a year is covered 0.7 times by its yearly operating cash.
Lower than 64% of Healthcare companies in India.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 65% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 85% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 83% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
NGL Fine-Chem Limited owes ₹0.40 for every ₹1 it owns. Net profit rose 128% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
28.6Investors pay ₹28.6 for every ₹1 of NGL Fine-Chem Limited's yearly profit, lower than 67% of Healthcare companies in India.
P/B ratio
4.97The share price is 4.97 times NGL Fine-Chem Limited's book value per share, higher than 52% of Healthcare companies in India.
Market cap
₹1,635 CrThe total market value of all of NGL Fine-Chem Limited's shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹329 CrWhat NGL Fine-Chem Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹532.92Net worth divided by the number of shares. The share price of ₹2,646 is 5.0 times this, which is the P/B above.
Return on equity (ROE)
17.4%NGL Fine-Chem Limited earned 17.4% on its shareholders' money over the last year, higher than 70% of Healthcare companies in India.
Owes vs Owns
0.40×NGL Fine-Chem Limited owes ₹0.40 for every ₹1 it owns (low), higher than 59% of Healthcare companies in India.
Dividend yield
0.06%NGL Fine-Chem Limited pays 0.06% of its share price as dividends a year, lower than 94% of dividend-paying Healthcare companies in India.
Revenue growth
+36%Revenue rose 36% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Profit growth
+128%Net profit rose 128% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Profit margin
9.7%NGL Fine-Chem Limited keeps ₹10 of every ₹100 of revenue as net profit.
Cash quality
0.90×Cash from NGL Fine-Chem Limited's business was 0.90× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
13.6×NGL Fine-Chem Limited's operating profit covered its interest costs 13.6 times in the year to Mar 2026.
Cash vs debt
Net debtNGL Fine-Chem Limited had ₹81 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is NGL Fine-Chem Limited's P/E ratio?
Investors pay ₹28.6 for every ₹1 of NGL Fine-Chem Limited's yearly profit, lower than 67% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For NGL Fine-Chem Limited: ₹1,635 Cr ÷ ₹329 Cr (31 Mar 2026) = 5.0.
What is NGL Fine-Chem Limited's return on equity?
NGL Fine-Chem Limited earned 17.4% on its shareholders' money over the last year, higher than 70% of Healthcare companies in India.
How much does NGL Fine-Chem Limited owe compared with what it owns?
NGL Fine-Chem Limited owes ₹0.40 for every ₹1 it owns (low), higher than 59% of Healthcare companies in India.
Does NGL Fine-Chem Limited pay a dividend?
Yes. NGL Fine-Chem Limited pays 0.06% of its share price as dividends a year, lower than 94% of dividend-paying Healthcare companies in India.
Is NGL Fine-Chem Limited's revenue growing?
Revenue rose 36% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.